TW200843757A - Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors - Google Patents

Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors Download PDF

Info

Publication number
TW200843757A
TW200843757A TW097111546A TW97111546A TW200843757A TW 200843757 A TW200843757 A TW 200843757A TW 097111546 A TW097111546 A TW 097111546A TW 97111546 A TW97111546 A TW 97111546A TW 200843757 A TW200843757 A TW 200843757A
Authority
TW
Taiwan
Prior art keywords
alkyl
compound
mmol
formula
group
Prior art date
Application number
TW097111546A
Other languages
English (en)
Chinese (zh)
Inventor
Fredrik P Marmsater
Mark C Munson
James P Rizzi
John E Robinson
Stephen T Schlachter
George T Topalov
Qian Zhao
Joseph P Lyssikatos
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of TW200843757A publication Critical patent/TW200843757A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW097111546A 2007-03-28 2008-03-28 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors TW200843757A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90855607P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
TW200843757A true TW200843757A (en) 2008-11-16

Family

ID=39731287

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097111546A TW200843757A (en) 2007-03-28 2008-03-28 Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Country Status (7)

Country Link
US (1) US20100144751A1 (cg-RX-API-DMAC7.html)
EP (1) EP2139888A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010522765A (cg-RX-API-DMAC7.html)
CN (1) CN101679422A (cg-RX-API-DMAC7.html)
CA (1) CA2682231A1 (cg-RX-API-DMAC7.html)
TW (1) TW200843757A (cg-RX-API-DMAC7.html)
WO (1) WO2008121687A2 (cg-RX-API-DMAC7.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009010728A (es) * 2007-04-03 2009-10-26 Array Biopharma Inc Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
EP2225252B1 (en) 2007-11-30 2012-06-27 Novartis AG C2-c5-alkyl-imidazole-bisphosphonates
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
US8895550B2 (en) 2008-08-19 2014-11-25 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
TWI496779B (zh) * 2008-08-19 2015-08-21 Array Biopharma Inc 作為pim激酶抑制劑之三唑吡啶化合物
US8987251B2 (en) 2008-08-19 2015-03-24 Array Biopharma Inc. Triazolopyridine compounds as PIM kinase inhibitors
EP2389373B1 (en) 2009-01-21 2017-05-17 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridyl or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
CA2764021C (en) 2009-06-05 2014-04-22 Pfizer Inc. Gpr 119 modulators
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도
EP2332917B1 (en) * 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
FR2952934B1 (fr) * 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2640699B1 (en) 2010-11-17 2015-10-07 Actelion Pharmaceuticals Ltd. Bridged spiro[2,4]heptane ester derivatives
DK2678329T3 (da) 2011-02-25 2016-02-22 Array Biopharma Inc Triazolopyridinforbindelser som pim-kinase-hæmmere
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
EA027418B1 (ru) 2011-06-27 2017-07-31 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013007768A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
CN104066730B (zh) 2011-10-14 2017-03-08 埃姆比特生物科学公司 杂环化合物及其作为iii型受体酪氨酸激酶调节剂的用途
MA37618B1 (fr) 2012-05-16 2017-08-31 Actelion Pharmaceuticals Ltd Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx
ES2855575T3 (es) 2012-06-26 2021-09-23 Janssen Pharmaceutica Nv Combinaciones que comprenden compuestos de 4-metil-[1,2,4]triazolo[4,3-a]quinoxalina como inhibidores de PDE2 e inhibidores de PDE10 para su uso en el tratamiento de trastornos neurológicos o metabólicos
KR102171706B1 (ko) 2012-07-09 2020-10-30 얀센 파마슈티카 엔.브이. 포스포디에스테라아제 10 효소의 억제제
AU2013324396B2 (en) 2012-09-28 2018-10-04 Vanderbilt University Fused heterocyclic compounds as selective BMP inhibitors
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
CN104597194B (zh) * 2015-01-15 2016-07-06 武汉轻工大学 3-氯-1,2-丙二醇的高效液相色谱-荧光检测方法
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
DK3684767T3 (da) 2017-09-22 2024-07-15 Jubilant Epipad LLC Heterocykliske forbindelser som pad-inhibitorer
AU2018352142B2 (en) 2017-10-18 2022-08-25 Jubilant Epipad LLC Imidazo-pyridine compounds as PAD inhibitors
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
SMT202400203T1 (it) 2017-11-24 2024-07-09 Jubilant Episcribe Llc Composti eterociclici come inibitori di prmt5
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3093527A1 (en) 2018-03-13 2019-09-19 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3765460A1 (en) 2018-03-14 2021-01-20 Vanderbilt University Inhibition of bmp signaling, compounds, compositions and uses thereof
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药(集团)股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
WO2022031928A1 (en) * 2020-08-05 2022-02-10 The General Hospital Corporation Salt inducible kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
WO2003092595A2 (en) * 2002-05-02 2003-11-13 Merck & Co., Inc Tyrosine kinase inhibitors
EP1656378A4 (en) * 2003-08-15 2011-05-11 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY
US20050256309A1 (en) * 2004-05-12 2005-11-17 Altenbach Robert J Tri-and bi-cyclic heteroaryl histamine-3 receptor ligands

Also Published As

Publication number Publication date
WO2008121687A2 (en) 2008-10-09
US20100144751A1 (en) 2010-06-10
JP2010522765A (ja) 2010-07-08
CA2682231A1 (en) 2008-10-09
EP2139888A2 (en) 2010-01-06
CN101679422A (zh) 2010-03-24
WO2008121687A3 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
TW200843757A (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
TW200900063A (en) Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
DK2861595T5 (en) Substituted tricyclic compounds as FGFR inhibitors
CN113874363A (zh) 蛋白质酪氨酸磷酸酶抑制剂
CN112939967B (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CN102149713B (zh) 吡啶并吡啶酮衍生物及其制备方法和治疗用途
TW200900404A (en) Pyrazolopyrimidine analogs and their use as mTOR kinase and PI3 kinase inhibitors
TW201127385A (en) N-containing heteroaryl derivatives as JAK3 kinase inhibitors
TWI781607B (zh) 一種免疫抑制劑、其製備方法和應用
TW202400601A (zh) 作為parp抑製劑的取代的三環類化合物及其用途
JP7357146B2 (ja) アザヘテロアリール化合物及びその使用
US20230257383A1 (en) Compound serving as btk inhibitor, preparation method therefor, and use thereof
TW202216720A (zh) 作為雄激素受體調節劑的吲哚化合物
CN112585138A (zh) 可用于治疗癌症的作为ErbB调节剂的4-取代的吡咯并[2,3-b]吡啶
CN115836064B (zh) 具有egfr抑制活性的三嗪衍生物及其制备方法和应用
US20110184013A1 (en) Imidazo[1,2-a]Pyridine Compounds As Receptor Tyrosine Kinase Inhibitors
AU2005295091A1 (en) Substituted biaryl quinolin-4-ylamine analogues
WO2018233526A9 (zh) 一种csf1r抑制剂及其制备方法和应用
JP2022502484A (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
WO2022213980A1 (zh) Tyk2抑制剂及其用途
WO2023160475A1 (zh) 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途
WO2023104043A1 (zh) 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
JP2024542221A (ja) 15-pgdh阻害剤及び使用
CN121226339A (zh) 一种苯并呋喃类化合物作为trpm3拮抗剂
CN118451080A (zh) 三环gpr65调节剂